Detalles de la búsqueda
1.
Multiparametric MRI and 18F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer.
Radiology
; 311(2): e231879, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38771185
2.
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
Br J Cancer
; 126(6): 907-916, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34912074
3.
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.
Oncologist
; 27(10): e783-e795, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36124924
4.
Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study.
BMC Cancer
; 22(1): 1365, 2022 Dec 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36581909
5.
The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer.
Br J Clin Pharmacol
; 88(3): 1170-1178, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34436788
6.
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Lancet Oncol
; 22(9): 1250-1264, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34388386
7.
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Int J Cancer
; 148(2): 385-395, 2021 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32965028
8.
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.
Eur J Nucl Med Mol Imaging
; 48(10): 3325-3334, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33686456
9.
Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study.
Clin Chem
; 66(6): 842-851, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32408351
10.
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
BMC Cancer
; 20(1): 884, 2020 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32928177
11.
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer.
Future Oncol
; 16(19): 1371-1384, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32469606
12.
Introducing Decision Aids into Routine Prostate Cancer Care in The Netherlands: Implementation and Patient Evaluations from the Multi-regional JIPPA Initiative.
J Cancer Educ
; 35(6): 1141-1148, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31278659
13.
Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
Prostate
; 78(5): 336-342, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29330943
14.
Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.
Br J Clin Pharmacol
; 84(1): 122-129, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28881501
15.
Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer.
Ther Drug Monit
; 40(2): 222-229, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29419723
16.
A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
Prostate
; 77(14): 1401-1407, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28853167
17.
Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
Br J Cancer
; 126(7): 1108, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35210590
18.
Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
BJU Int
; 120(5): 659-665, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28370948
19.
The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited.
Prostate
; 76(10): 897-904, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26989049
20.
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.
Prostate
; 76(1): 32-40, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26390914